News

October 16, 2017

Claritas will be attending ASHG 2017 in Orlando, Florida this week! Stop by our booth (#761) to learn more about our newest offerings and check out our poster (#2507) on "Detecting Mitochondrial Heteroplasmy for Clinical Diagnostics" which will be presented at 2:00pm on Thursday by John Thompson, PhD and Chief Technology Officer, and Eric White, PhD and Director of Assay and Technology Development....

September 25, 2017

Claritas Genomics has launched the new and improved Bone Marrow Failure Region of Interest NGS test, complete with 8 additional genes and 19 deep intron variants. The Bone Marrow Failure Region of Interest test was initially released in August, 2016. For more details on the updated assay, please visit our Bone Marrow Failure Region of Interest test page....

June 22, 2017

Claritas Genomics is pleased to announce it has received approval from the New York State Department of Health for three Region of Interest tests and Mitochondrial DNA analysis for the Claritas Clinical Exome. For the full list of NYS approved offerings, please visit our For New York State Providers page. Read the full press release...

May 03, 2017

The HLH Region of Interest assay is designed to assess genes that may cause autosomal recessive or X-linked recessive forms of primary HLH. Developed in collaboration with experts in the Division of Immunology at Boston Children’s Hospital, this Region of Interest evaluates 20 genes related to the known causes of HLH within a rapid turnaround time. More information can be found here....

January 30, 2017

Claritas is pleased to announce the addition of the mitochondrial DNA analysis to their Flagship Claritas Clinical Exome. When ordered, the mitochondrial genome and exome are sequenced simultaneously by deep NGS sequencing. More information is available here....

January 05, 2017

On January 4, 2017, Claritas Genomics received the New York State Clinical Laboratory Permit with specific approval for the Claritas Clinical Exome and the Pediatric Neurology Region of Interest. Read the Press Release here. ...

January 05, 2017

Dr. Stephanie Hallam joined Claritas Genomics on November 29, 2016, as Vice President of Molecular Diagnostics. Read the full press release here....

January 03, 2017

A Washington Post article, published on December 30, 2016, describes the Weekes family's journey with Boston Children's Hospital to find a molecular diagnosis for their son Quinlan, who has experienced seizures and other serious medical issues since birth. The article describes Claritas Genomics' founder Dr. Tim Yu's use of the WuXi NextCODE platform to interpret Quinlan's DNA sequence which resulted in a diagnosis that explained Quinlan's...

October 27, 2016

Claritas Genomics employees presented three posters at ASHG 2016 in Vancouver, Canada. John Thompson, PhD and Chief Technology Officer, presented on "Improved sensitivity for clinically relevant variants using orthogonal sequencing." Eric White, PhD and Director of Assay and Technology Development, presented on "Improving coverage of poorly sequenced regions in clinical exomes." Natalie Vena, GC and Genetic...

October 12, 2016

Claritas Genomics’ Elizabeth Mullady, MLS(ASCP), MHA, Director of Quality Assurance and Regulatory Affairs speaks on October 18, 2016 at the 10th annual Lab Quality Confab in New Orleans. Ms. Mullady and co-presenter Randall Querry of the American Association for Laboratory Accreditation discuss “Lessons Learned at Claritas from Simultaneous Accreditation to CLIA and ISO 15189: Combining the World’s Most Accepted QMS with CLIA.” Read more about their talk by visiting...

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.